Sibutramine/Meridia. Abbot labs voluntarily pulled sibutramine from the us market in 2010 because clinical trials showed increased risk of heart attack and stroke. Many other countries followed suit. It inhibits central reuptake of dopamine, norepinephrine, and serotonin -- serotonin mechanism may increase satiety; ne one may increase metabolic rate. Some generic forms may be available, but not by prescription.